Mexico City, November 6 2024.
Recently, the head of the Ministry of Health, David Kershenobich, met with the heads of the health ministries of the 32 states of the Mexican Republic, as well as with directors of public institutions to present the work program of the Ministry of Health for the administration of President Claudia Sheinbaum.
At the meeting, the following points were highlighted as priorities:
- Strengthen the so-called IMSS-BIENESTAR system, as the axis of the current administration.
- Focus on preventive medicine and a primary care system.
- House-to-House health program, focused on the elderly.
- Program to reduce dengue fever.
In addition, Kershenobich highlighted the importance of collaboration among Mexico’s 32 states.
In connection with the above, it was also announced that the Ministry of Health will supervise the purchase of medicines and medical supplies. These purchases will be made according to the needs defined by the health institutions and will be carried out through Laboratorios de Biológicos y Reactivos de México (Birmex). It is expected that purchases will be made on a biannual basis through public bids. The next public bid, for the period 2025-2026, has been announced for December of this year.
The complete notes can be found (in Spanish) at the following links: 416. David Kershenobich presenta plan de trabajo 2024-2030 a secretarios de las 32 entidades y directores de instituciones del sector Salud | Secretaría de Salud | Gobierno | gob.mx y Anuncia presidenta Claudia Sheinbaum nuevo mecanismo para compra de medicamentos e insumos médicos con transparencia y cero corrupción | Presidencia de la Republica | Gobierno | gob.mx.
It is well known that the participation of the pharmaceutical industry is essential for the country’s drug supply. Therefore, for public bidding procedures, it is key for innovative pharmaceutical companies to review their patent portfolios in order to determine which patents are relevant in relation to the products that the government intends to acquire and which patents may be subject to compensation for the time lost in their processing and achieve a real and effective validity, according to the criteria of the Supreme Court of Justice that our firm successfully obtained. In addition to the possibility of obtaining protections of clinical data and compensation for delays in the regulatory proceedings.
The partners and associates in the litigation and life sciences practices of the firm are available to provide you with any additional information or advice you may need.
Sincerely,
Adolfo Athié Cervantes
Mariana González Vargas
Erika Rodríguez Kushelevich
